Course Outline
Click on the links below to preview selected pages from this course.
- Introduction
- Current Practice of Room Temperature Platelets
- Cold-Stored Platelets
- Re-Introducing Cold-Stored Platelets
- Advantages of Cold-Stored Platelets
- Disadvantages of Cold-Stored Platelets
- Which of the following is a primary advantage of extended shelf life in cold-stored platelets (CSPs)?
- A potential concern regarding the widespread implementation of cold-stored platelets (CSPs) is:
- Cold-Stored Platelet Viability
- Impact of Cold Storage on Platelet Viability: Metabolic Suppression
- Impact of Cold Storage on Platelet Viability: Mitochondrial Dysfunction
- Which of the following is a primary consequence of the metabolic slowdown induced by cold storage in platelets?
- Cold storage can affect mitochondrial function in platelets by:
- Cold-Stored Platelet Function
- Cold-Stored Platelets and Bleeding Risk
- Cold-Stored Platelets and Bleeding Risk
- Which of the following is a potential way cold-stored platelets (CSPs) could contribute to increased bleeding risk?
- A patient with which of the following conditions might be at a higher risk for complications when receiving cold-stored platelets (CSPs)?
- Cold-Stored Platelets and Transfusion Practice
- Trauma and Active Bleeding
- Challenges of Traditional Platelet Supply
- Surgical Procedures
- A potential advantage of using cold-stored platelets (CSPs) in a trauma patient with severe bleeding is:
- A primary reason why maintaining consistent platelet supplies in remote locations is difficult with room temperature platelets (RTPs) is:
- A potential advantage of using cold-stored platelets (CSPs) during surgery is:
- Research and Clinical Implementation
- Current Clinical Trials
- Regulatory Hurdles and Approval
- Logistics and Cost Effectiveness
- A primary goal of current clinical trials on cold-stored platelets (CSPs) is to determine if they:
- To gain regulatory approval for widespread use, cold-stored platelets (CSPs) must demonstrate:
- Specific Patient Populations
- Cold-Stored Platelets in Neonates and Pediatrics
- Cold-Stored Platelets in Patients with Bleeding Disorders
- Cold-Stored Platelets in Thrombocytopenia
- A potential advantage of using cold-stored platelets (CSPs) in neonates and children is:
- What is the potential benefit of using cold-stored platelets (CSPs) in patients with bleeding disorders?
- Thrombocytopenia, a condition crucial to the potential use of cold-stored platelets (CSPs), is characterized by:
- Future Directions
- Rejuvenation Techniques
- Optimizing Storage Solutions
- The Ethics of Cold-Stored Platelet Adoption
- A potential rejuvenation strategy for cold-stored platelets involves:
- A primary goal of optimizing storage solutions for cold-stored platelets (CSPs) is to:
- The Future of Transfusion Medicine
- References
Additional Information
Level of Instruction: Intermediate
Intended Audience: Medical laboratory scientists, medical laboratory technicians, laboratory management, and transfusion medicine. This course may also be appropriate for medical laboratory science students and pathology residents.
Author Information: Matt Hukill, PhD, MS, MBA, MLS(ASCP)
CMSBB
CM, is a specialist in immunohematology who currently works at the American Red Cross in Durham, NC. A dedicated educator, he serves as a trainer, instructor, and mentor in the Blood Bank Technology program, as well as working part-time as an AABB assessor. His experience in the field also includes managing an immunohematology reference laboratory (IRL), working in transfusion services in major hospital systems, as well as developing educational curricula and authoring technical documents.
Reviewer Information: Stephanie Aunspach, MLS(ASCP)CM, has over seven years of experience in transfusion medicine and currently serves on the board of the North Carolina Association of Blood Bankers (NCABB). Her experience in the field includes working in transfusion services in a major hospital system, working in an immunohematology reference laboratory (IRL), and change management for a company producing plasma-derived medicines.
